NEXGEL, Inc. (NASDAQ:NXGL) has signed an asset purchase and exclusive licensing agreement with Celularity, Inc. to obtain rights to Celularity’s commercial-stage regenerative biomaterials portfolio, the companies announced. The products focus on applications including tendon repair, skin grafts and bone regeneration.
The agreement, dated March 6, 2026, carries a total potential value of up to $35 million. It includes an upfront payment of $15 million in cash and up to $20 million in additional milestone-based payments. The transaction may also involve manufacturing arrangements and a sublease agreement. Completion of the deal is contingent upon NEXGEL securing financing to cover the initial payment.
Publicly disclosed on March 10, 2026, the acquisition is described by NEXGEL as the most significant development in the company’s history. Management expects the deal to approximately triple annual revenue to around $35 million and move the company into profitability once the transaction closes.
The portfolio includes six established regenerative biomaterial products that are already generating revenue, have insurance reimbursement coverage and have been used clinically for more than a decade. In addition, the acquisition includes a development pipeline featuring three planned 510(k) regulatory submissions expected in 2026, 2027 and 2028. The transaction will also bring in a commercial and scientific team with experience in the field, which NEXGEL believes will help expand its sales capabilities and strengthen its position in the medical technology sector.
To support the transaction, NEXGEL plans to complete approximately $14.9 million in additional financing during the first half of 2026. The proceeds are expected to help fund the upfront payment and support integration of the acquired assets.
The company also said it is in discussions with an accredited institutional investor regarding a potential equity line of credit of up to $100 million in newly issued common shares. Such a facility could provide flexible capital to support future expansion and help scale a combined regenerative biomaterials and hydrogel platform across multiple healthcare and consumer markets.
More about NexGel Inc
NEXGEL, Inc., based in Langhorne, Pennsylvania, develops and supplies healthcare, beauty and over-the-counter products using high-water-content hydrogel technologies designed to be gentle on the skin. The company has more than 20 years of experience producing electron-beam, cross-linked hydrogels.
Its portfolio includes brands such as SilverSeal, Hexagels, Turfguard, Kenkoderm and Silly George, while it also manufactures products for several major consumer healthcare companies through contract partnerships.
NEXGEL operates at the intersection of consumer health and medical technology, applying its hydrogel platform across wound care, dermatology and cosmetic applications. Its products are sold both under its own brands and through commercial partners, positioning the company as a specialized materials provider in both regulated medical markets and the broader OTC sector.